Mizuho Maintains Buy on Amylyx Pharma, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Amylyx Pharma (NASDAQ:AMLX) and increased the price target from $27 to $32. This adjustment reflects a positive outlook on the company's future performance.
March 08, 2024 | 11:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh has reaffirmed a Buy rating on Amylyx Pharma and raised the price target from $27 to $32, indicating a bullish outlook on the stock.
The increase in price target by a reputable analyst such as Graig Suvannavejh from Mizuho signals a strong vote of confidence in Amylyx Pharma's future performance and potential. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100